Novo Nordisk stock falls as 2030 growth targets disappoint

Published on 09/22/2026 at 14:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock closed at DKK 260.00 on September 21, 2026, down 7.65 percent. The 2030 targets depend on Wegovy and CagriSema.

Modernes nordisches Forschungszentrum, Glasfassade, Skandinavisches Architekturdesign — Novo Nordisk A/S (DK0062498333): nordisches Forschungszentrum mit Glasfassade und klaren skandinavischen Linien, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0062498333) closed at DKK 260.00 on Nasdaq Copenhagen on September 21, 2026, down 7.65 percent from the previous close. The decline followed the company investor day, where medium-term growth targets failed to provide the reassurance investors had expected.

Growth targets face execution risk

According to TradingView on September 22, 2026, Novo Nordisk presented mid-term revenue growth in the mid-single-digit range for 2026 through 2030 and expects adjusted operating margins to remain broadly stable.

The targets depend on the oral Wegovy pill and the CagriSema rollout, while a competitive zenagamtide obesity treatment profile is expected to be delivered in phase 3 trials in 2028, the same TradingView report said. That dependency makes the 2028 development milestone a material counter-factor to the near-term valuation reset.

Analyst targets move lower

The analyst response was mixed but included several target cuts. According to MarketScreener on September 22, 2026, Jefferies lowered its target from DKK 285.00 to DKK 275.00 and maintained Hold, while Deutsche Bank cut its target from DKK 265.00 to DKK 245.00 and maintained Sell.

Other published targets show the disagreement. TipRanks reported on September 21, 2026, that Jefferies retained Hold with a DKK 275.00 target, while Zonebourse listed JP Morgan at Neutral with a DKK 260.00 target and Jefferies at DKK 275.00.

Stock remains below yearly high

Investing.com reported a September 22, 2026 price of DKK 256.90, compared with a previous close of DKK 260.00 and a 52-week range of DKK 224.30 to DKK 410.00. The DKK 1.14 trillion market capitalization places the stock about 37 percent below the reported 52-week high, using the same quoted range.

The valuation debate is therefore numerical rather than rhetorical: the published average target was DKK 308.90, while the stock traded at DKK 256.90 on September 22, 2026. The gap reflects potential upside in the consensus calculation, but the 2026 to 2030 targets leave execution of the next obesity medicines as the decisive operating variable.

Closing price and valuation gap

Novo Nordisk stock was quoted at DKK 256.90 on Nasdaq Copenhagen on September 22, 2026, after a previous close of DKK 260.00. The reported 52-week range was DKK 224.30 to DKK 410.00, with market capitalization of DKK 1.14 trillion as of September 22, 2026.